Form 8-K - Current report:
SEC Accession No. 0001420720-24-000032
Filing Date
2024-07-26
Accepted
2024-07-26 09:03:41
Documents
15
Period of Report
2024-07-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20240723x8k.htm   iXBRL 8-K 36504
2 EX-10 ibio-20240723xex10.htm EX-10 100450
  Complete submission text file 0001420720-24-000032.txt   287094

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20240723.xsd EX-101.SCH 4161
4 EX-101.DEF ibio-20240723_def.xml EX-101.DEF 3992
5 EX-101.LAB ibio-20240723_lab.xml EX-101.LAB 14533
6 EX-101.PRE ibio-20240723_pre.xml EX-101.PRE 10732
17 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240723x8k_htm.xml XML 4825
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 241143704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)